Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) released its earnings results on Wednesday. The company reported $1.08 EPS for the quarter, Zacks reports. Recordati Industria Chimica E Farmaceutica had a net margin of 17.81% and a return on equity of 35.19%. The business had revenue of $834.86 million for the quarter.
Recordati Industria Chimica E Farmaceutica Price Performance
Shares of Recordati Industria Chimica E Farmaceutica stock remained flat at $55.88 during trading on Friday. The stock has a 50-day moving average price of $56.69 and a 200-day moving average price of $62.06. The company has a market capitalization of $11.53 billion, a price-to-earnings ratio of 21.14 and a beta of 0.23. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.16 and a current ratio of 1.64. Recordati Industria Chimica E Farmaceutica has a 12 month low of $55.88 and a 12 month high of $56.95.
Analysts Set New Price Targets
A number of analysts recently commented on RCDTF shares. Barclays upgraded shares of Recordati Industria Chimica E Farmaceutica from a “strong sell” rating to a “hold” rating in a report on Thursday, February 12th. Kepler Capital Markets upgraded shares of Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 3rd. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy”.
About Recordati Industria Chimica E Farmaceutica
Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.
The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.
See Also
- Five stocks we like better than Recordati Industria Chimica E Farmaceutica
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Recordati Industria Chimica E Farmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati Industria Chimica E Farmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
